Generic vs brand forms of direct acting antivirals for hepatitis C virus treatment in Egyptian children

Table 1 Demographic data of children receiving generic vs branded direct acting antivirals, n (%)

Variable	Patients who received Ledisbuvir (n = 43)	Patients who received Harvoni® (n = 73)	P value
Age (year), mean ± SD	12.2 ± 2.5	13.4 ± 2	0.005
Range	7-18	8-18
Sex			1.0
Male	26 (60.5)	41 (56.2)
Female	17 (39.5)	32 (43.8)
Risk factors for HCV acquisition
Maternal HCV	4 (9.3)	26 (35.6)	0.002
Intrafamilial cases	12 (27.9)	29 (39.7)	0.2
Blood products transfusion	32 (74.4)	29 (39.7)	< 0.001
Hospitalization	40 (93)	51 (69.9)	0.004
Previous operations	25 (58.1)	39 (53.4)	0.7
Dental procedure	18 (41.9)	29 (39.7)	0.8
Associated co-morbidities			< 0.001
No	8 (18.6)	39 (53.4)
Yes	35 (81.4)	34 (46.6)

Student’s t test was used for mean (Parametric) and Pearson χ² or Fisher’s exact test for categorical variables. HCV: Hepatitis C virus.